Temps réel Euronext Paris  -  17:29 24/06/2022
0.0640 EUR   -4.33%
23/06NOXXON : la nouvelle stratégie saluée par le marché
23/06NOXXON annonce une mise à jour de sa stratégie de développement suite au fort bénéfice clinique observé avec NOX-A12 en association avec la radiothérapie et le bevacizumab dans le cancer du cerveau
13/06NOXXON : collaboration avec le NCI américain
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur NOXXON PHARMA N.V.
24/06Noxxon announces corporate action to start the parity period
23/06NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observe..
14/06Noxxon enters into collaboration with us national cancer institute to characterize effe..
13/06NOXXON Pharma N.V. Enters into Amaterial Transfer Agreement with the U.S. National Canc..
10/06NOXXON PHARMA N : KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma
06/06Noxxon presents full top-line results from nox-a12 phase 1/2 gloria trial in glioblasto..
02/06Noxxon to host key opinion leader webinar on gloria study top-line results of nox-a12 &..
31/05NOXXON announces convocation of the 2022 annual general meeting of shareholders
26/05NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASC..
20/05Noxxon amends equity-linked facility with atlas
19/05Noxxon Obtains Additional $1 Million in Remaining Tranches of Equity-linked Facility
17/05Noxxon announces results of the extraordinary general meeting of shareholders
11/05Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments
22/04NOXXON Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2021
22/04Noxxon announces eur2.375 million financing under agreement with atlas
22/04NOXXON Pharma N.V. Auditor Raises 'Going Concern' Doubt
07/04Top-line results from noxxon's nox-a12 phase 1/2 gloria trial in brain cancer to be pre..
06/04NOXXON PHARMA N : Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain ca..
06/04Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to B..
24/03NOXXON Announces Top-Line Data of Phase 1/2 GLORIA Study With NOX-A12 in Partially Rese..
31/01Noxxon announces eur2.375 million financing under agreement with atlas
31/01Cancer-Focused Biotech Noxxon Secures Additional $2.7 Million Financing
27/01Noxxon - half-yearly report on the liquidity contract with invest securities
10/01Noxxon provides progress update on the expansion arms of the phase 1/2 gloria trial wit..
07/01NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial Wit..
06/01Noxxon provides update on evaluation of nox-a12 in non- oncology indication by a leadin..
05/01NOXXON Pharma N.V. Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication ..
03/01NOXXON Pharma N.V. announced that it expects to receive €17 million in funding
2021Noxxon Gets Additional $19 Million Funding From Atlas Special Opportunities
2021NOXXON PHARMA N : secures Euro 17 million expansion of equity-linked facility with Atlas t..
2021NOXXON Pharma N.V. Announces Appointment of Bryan Jennings as Additional Statutory Dire..
2021NOXXON PHARMA N : announces results of the extraordinary general meeting of shareholders
2021NOXXON PHARMA N : to participate in banking and investor conferences in January and Februa..
2021GLOBAL MARKETS LIVE : Intel, Tesla, Facebook, ABB, SGS...
2021NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12..
2021NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in..
2021NOXXON : New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presente..
2021NOXXON PHARMA N : Presentation by Dr. Frank Giordano at the Society for Neuro-Oncology (SN..
2021Noxxon to host key opinion leader webinar on nox-a12 and radiotherapy combination, a di..
2021NOXXON TO HOST KEY OPINION LEADER WE : a differentiated and promising new approach to trea..
2021NOXXON PHARMA N : announces convocation of an Extraordinary General Meeting of shareholder..
2021GLOBAL MARKETS LIVE : Euronext, AMC, PayPal, Roblox, UniCredit...
2021NOXXON to present at the third edition of Investir Day on November 23 in Paris, France
2021William Bryan Jennings
2021NOXXON Provides Update on Timing for Upcoming Trials of NOX-A12 in Pancreatic and Brain..
2021NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain..
2021NOXXON Pharma N.V. Appoints Bryan Jennings as Chief Financial Officer, Effective Novemb..
2021Experienced financial executive, Bryan Jennings, joins NOXXON as CFO
2021GLOBAL MARKETS LIVE : HSBC, PayPal, Tesla, Daimler, Intel...
2021NOXXON PHARMA N : Reports H1 2021 Financial Results and Provides Business Update
2021NOXXON Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2021
2021NOXXON PHARMA N : 2021, Half-Year Financial Report as of 30 June 2021
2021NOXXON Announces Planned Expansion of Phase 1/2 NOX-A12 Brain Cancer Trial
2021NOXXON PHARMA N : announces planned expansion of Phase 1/2 NOX-A12 brain cancer trial
2021NOXXON PHARMA N : announces upcoming oral presentation at the Society for Neuro-Oncology A..
2021GLOBAL MARKETS LIVE : Sanofi, ASML, Apple, United Airlines, Netflix...
2021NOXXON PHARMA N : Enrolls Last Patient For Phase 1/2 Trial Of Brian Cancer Treatment
2021NOXXON Pharma N.V Enrolls Last Brain Cancer Patient in Dose Escalation Portion of GLORI..
2021NOXXON PHARMA N : enrolls last brain cancer patient in dose escalation portion of GLORIA s..
2021NOXXON PHARMA N : to attend the German Fall conference on September 6 & 7, 2021
2021GLOBAL MARKETS LIVE : Robinhood, Bayer, MetLife, Uber, WPP...
2021NOXXON PHARMA N : to Expand Ongoing Early-Stage Brain Cancer Study; Shares Down 5%
2021NOXXON Provides Update on NOX-A12 Clinical Programs
2021NOXXON PHARMA N : Half-yearly report on the liquidity contract with Invest Securities
2021GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
2021MERCK : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in Mid-Stage..
2021NOXXON PHARMA N : enters second clinical collaboration with MSD to evaluate NOX-A12 in com..
2021NOXXON PHARMA N : Martine J. van Vugt
2021GLOBAL MARKETS LIVE : Facebook, Toshiba, Fedex, Nike, Microsoft...
2021Noxxon Pharma N.V. Announces Board Changes
2021NOXXON Pharma N.V. Announces Positive Results from the Second Cohort in its Phase 1/2 S..
2021CORRECTED PRESS RELEASE : NOXXON announces positive results from second cohort in Phase 1/..
2021GLOBAL MARKETS LIVE : Tesla, AB Volvo, Credit Suisse, Amazon, Tyson Foods...
2021La fiesta aún no ha terminado
2021EN DIRECTO DESDE LOS MERCADOS : Stellantis, Amazon, U-Blox, Cloudera, Tesla, Credit Suisse..
1  2  3  4  5  6Suiv.
Prochain événement sur NOXXON PHARMA N.V.